POWAY, Calif., Aug. 5, 2020 /PRNewswire/ — Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, has announced that enrollment is officially complete for their FDA approved stem cell clinical trial for treatment of knee osteoarthritis. 38 patients are participating in the clinical trial to have one knee treated with their own stem cells.
To participate in the clinical trial, patients must be suffering from knee osteoarthritis and meet enrollment criteria. Clinical trial participants undergo a liposuction procedure to collect a sample of adipose (fat) tissue. This tissue is processed at PSC’s FDA inspected laboratory where technicians isolate and extract each patient’s stem and regenerative cells. Each patient receives one injection of their own stem cells into the affected knee.
This enrollment milestone is an important step forward in the completion of the clinical trial. PSC CEO, Dr. Robert Harman, stated, “We are fortunate to have a fully enrolled trial which will allow us to move forward in the FDA approval process. While stem cells